Over half a million new cases of hepatocellular carcinoma (HCC) are diagnosed each year, being the main malignant hepatobiliary disease and the third cause of cancer-related death worldwide ([@bib30]). Hepatocellular carcinoma is associated with cirrhosis and hepatic dysfunction in 80% of patients, which makes its prognosis and treatment more difficult than in many other cancers ([@bib52]). Dysregulation of cellular proliferation, apoptosis, and angiogenesis is frequently associated with HCC development and progression, and understanding these molecular pathways becomes essential to the development of effective therapies ([@bib15]). Like some other solid tumours, HCC growth relies on new vessels formation, required for nutrients and oxygen supply ([@bib27]). Incipient success of anti-angiogenic therapy in similar tumours ([@bib29]; [@bib32]) suggests that adjuvant anti-angiogenic agents combined with chemotherapy or radiotherapy may be particularly attractive approaches to target tumour and endothelial cells, and thus, to enhance treatment efficacy ([@bib54]).

Deficit of oxygen availability within the tumour microenvironment is highly associated with tumour progression ([@bib1]). Oxygen homeostasis is directly regulated via hypoxia inducible factor 1 (Hif1*α*). Whereas normoxia leads to its ubiquitination and subsequent proteasomal degradation, under hypoxia, Hif1*α* is stabilised and able to translocate to the nucleus, where it induces the expression of several genes such as erythropoietin (EPO), nitric oxide synthases, and vascular endothelial growth factor (VEGF) ([@bib59]). Vascular endothelial growth factor is a secreted protein that acts as a potent mitogen for vascular endothelial cells and some other cell types, being one of the main regulatory factors in angiogenesis and neovascularisation ([@bib21]). Moreover, VEGF appears frequently hyperexpressed in HCC tissues, which consistently correlates with tumour size and histologic tumour grade ([@bib58]). Signal transducer and activator of transcription 3 (STAT3) is a well-known oncogene in HCC and in some other tumour types ([@bib31]). Besides its participation in normal physiological processes, it has been found constitutively activated in cancers, transcriptionally activating oncogenes encoding for apoptosis inhibitors and cell-cycle regulators, such as Bcl-x(L), cyclin D1, and c-Myc ([@bib60]). Many studies suggest that, like Hif1*α*, STAT3 also behaves as an angiogenesis inductor involved in VEGF expression; activated via phosphorylation, it enhances Hif1*α* stability and acts as a co-activator under hypoxia ([@bib34]). Interestingly, both STAT3 and Hif1*α* have been associated in mediating VEGF transcription, and the presence of regulatory sites located in high proximity within its promoter suggests their close cooperation in the transcriptional regulation of this growth factor ([@bib46]).

Nowadays melatonin, the main product of the pineal gland, has attracted increasing attention because of its protective role in several pathophysiological situations, including different cancer types, where it exerts oncostatic effects ([@bib28]; [@bib19]; [@bib22]; [@bib14]; [@bib24]; [@bib23]; [@bib44]; [@bib6]; [@bib12]; [@bib25]; [@bib7], [@bib9]). Our group has shown the melatonin oncostatic activity in HepG2 liver tumour cells, highlighting its pro-apoptotic properties through upregulation of cell death-related processes ([@bib41]; [@bib8], [@bib7], [@bib9]). In addition, it has been recently reported a mechanism by which melatonin sensitises human hepatoma cells to endoplasmic reticulum stress and induces apoptosis by downregulating COX-2 expression, increasing the levels of CHOP and decreasing the Bcl-2/Bax ratio ([@bib62]). Melatonin anti-angiogenic properties have been reported both in *in vivo* ([@bib13]; [@bib17]) and *in vitro* models, implementing the existing knowledge regarding to its oncostatic role ([@bib36]). Moreover, a significant decline in the serum levels of VEGF has been found in metastatic cancer patients with different histotypes, including HCC, when treated with melatonin, which suggests that its ability to control tumour growth could be related, at least in part, to its anti-angiogenic features ([@bib40]). However, the precise mechanism that underlies melatonin anti-angiogenic effects in HCC has not been fully elucidated. Herein, the present research was aimed to assess melatonin action on tumour angiogenesis in an *in vitro* model of HCC, focusing on its ability to interfere with the transcriptional activation of VEGF via Hif1 and STAT3.

Materials and methods
=====================

Cell culture
------------

Human HepG2 hepatocarcinoma cells were obtained from the American Type Culture Collection (Manassas, VA). Stock cells routinely were grown as monolayer cultures in Dulbecco\'s Modified Eagle\'s Medium (DMEM), supplemented with 10% fetal bovine serum (FBS), penicillin (100 U ml^−1^), streptomycin (100 *μ*g ml^−1^), glutamine (4 mℳ), and pyruvate (100 *μ*g ml^−1^) in a humidified 5% CO~2~ atmosphere at 37 °C and the medium was changed every other day. Cell culture reagents were from Gibco (Life Technologies, Madrid, Spain). Melatonin was obtained from Sigma (St Louis, MO, USA). Confluent HepG2 cells growing in complete media were replated in 9.6 cm^2^ culture dishes, at a density of 150 000 cells/plate, in 2 ml of complete medium. After 24 h, the plating medium was replaced with fresh medium containing melatonin dissolved in DMSO (0.2% DMSO final concentration in the plate). Two melatonin concentrations were tested, 1 nℳ (within the 0.3--1.2 nℳ physiological range), and 1 mℳ as a supraphysiological/pharmacological concentration ([@bib17]). CoCl~2~ was added at a final concentration of 100 *μ*ℳ to mimic hypoxia. Among all the divalent metals that act as hypoxic mimetics, CoCl~2~ has shown to induce hypoxia, increasing Hif1*α* stability by antagonising Fe^+2^, an essential cofactor required for oxygen to interact with prolyl hydroxylases (PHDs) and degradate Hif1*α* ([@bib4]). Besides, our dose of cobalt has been previously used to induce hypoxia with non-toxic effects ([@bib18]). For inhibition studies, hepatocytes were incubated in the presence or absence of 10 *μ*ℳ Stattic (Tocris, Bristol, UK) for 1 h before treatment.

Western blot analysis
---------------------

After treatments, cultured cells were washed twice with ice-cold PBS and lysed by adding ice-cold RIPA buffer containing 50 mℳ Tris--HCl pH 7.4, 150 mℳ NaCl, 2 mℳ EDTA, 0.1% Triton X-100, 10% sodium deoxycholate, 10% SDS, 1 mℳ NaF and protease cocktail inhibitor (Roche, Basel, Switzerland) and scraped off the plate. The extract was transferred to a microfuge tube and centrifuged for 10 min at 15 000 **g**. Equal amounts of the supernatant protein (20 *μ*g) were separately subjected to SDS--PAGE and transferred onto a PVDF membrane (Bio-Rad, Hercules, CA, USA). Primary antibodies were diluted in blocking solution and incubated overnight at 4 °C with polyclonal antibody to VEGF (rabbit, 1 : 1000 dilution; Abcam, Cambridge, UK), Hif1*α* (rabbit, 1 : 1000 dilution; Abcam), Phospho-Stat3 (Tyr705) (D3A7) from mouse and Stat3 from rabbit 1 : 100 dilution (Santa Cruz, Santa Cruz, CA, USA). Equal loading of protein was demonstrated by probing the membranes with a rabbit anti *β*-actin polyclonal antibody (1 : 2000 dilution; Sigma). After washing with TBST, the membranes were incubated for 1 h at room temperature with secondary horseradish peroxidase (HRP)-conjugated antibody (1 : 4000; Dako, Glostrup, Denmark) and visualised using ECL detection kit (Amersham Pharmacia, Uppsala, Sweden). The density of the specific bands was quantified with an imaging densitometer (Scion Image, Maryland, MA, USA).

Real-time reverse transcriptase PCR
-----------------------------------

For real-time reverse transcriptase PCR (RT--PCR), confluent HepG2 cells growing in complete media were replated in 6-well culture plate, at a density of 150 000 cell/well in a total volume of 2 ml of complete medium. After treatment, total RNA was obtained by using a Trizol reagent (Applied Biosystems, Carlsbad, CA, USA) and quantified by spectrophotometry (Nanodrop 1000; Thermo Scientific, Waltham, MA, USA). Residual genomic DNA was removed by incubating RNA with RQ1 RNase-free DNase (Promega, Madison, WI, USA). First-strand cDNA was synthesised using M-MLV RT (Roche Molecular Systems), and the negative control (no transcriptase control) was performed in parallel. cDNA was amplified using FastSt art TaqMan Probe Master (Roche) on a StepOnePlus Real-Time PCR Systems (Applied Biosystems). TaqMan primers and probes for Hif1*α* (NM_001530 and Hs00153153_m1) and VEGF (NM_001025366 and Hs00900055_m1) genes were derived from the commercially available TaqMan Gene Expression Assays (Applied Biosystems). Relative changes in gene expression levels were determined using the 2^-ΔΔCT^ method ([@bib16]). The cycle number at which the transcripts were detectable (CT) was normalised to the cycle number of *β*-actin detection.

Tube formation assay
--------------------

Basement membrane extracellular matrix (Matrigel, BME, BD Bioscience, San Jose, CA, USA) was thawed at 4 °C overnight. A 96-well plate and 200 *μ*l pipette tips were also kept at 4 °C overnight and both the plate and tips were placed on ice during the entire experiment. In all, 50 *μ*l of Matrigel was loaded in each well of the 96-well plate and the plate was incubated at 37 °C in a tissue culture incubator for 30 min to allow the matrix to polymerise. Trypsinised human umbilical vein endothelial cells (HUVECs) from a primary culture with rare or non expression of endogenous VEGF were mixed with EBM-2 supplemented with VEGF (20 ng ml^−1^) or the conditioned media (CM) from HepG2 cells incubated under hypoxia (CoCl~2~) with or without the pharmacologic concentration (1 mℳ) of melatonin for 24 h, making the appropriate cell density (25 000 cells/well) and added on top of the gel in the 96-well plate. The plate was then incubated at 37 °C in a tissue culture incubator and the formation of the capillary-like tubes was observed after 6 h. Wells were imaged using a Nikon microscope. Quantification of tube formation was assisted by S.CORE, a web-based image analysis system (S.CO BioLifescience, Munich, Germany). Tube formation indices represent the degree of tube formation. The indices were calculated using the following equation: (tube formation index)=(mean single tube index)^2^ × (1−confluent area) × (number of branching points/total length skeleton). The values of the variables used in the equation were obtained automatically by S.CORE.

Quantitation of VEGF production
-------------------------------

Media were collected from 200 000 cells in 6-well culture plates and centrifuged at 800 r.p.m. for 4 min at 4 °C to remove cellular debris and then stored at 70 °C. Vascular endothelial growth factor in the medium was measured by using the Quantikine human VEGF ELISA kit from R&D Systems (Minneapolis, MN, USA) according to manufacturer\'s instruction.

Hif1*α* transcription activity assay
------------------------------------

The Hif1*α* transcriptional activity was analysed by Hif1*α* transcription factor assay using TransAM HIF-1 transcription factor assay kit (Active Motif, Carlsbad, CA, USA) according to manufacturer\'s instructions. Briefly, nuclear extracts were added onto 96-well microplate coated with oligonucleotides containing hypoxia response element (HRE) (5′-TACGTGCT-3′) from the EPO gene. The HIF dimers present in nuclear extracts bind with high specificity to this response element and are subsequently detected with an antibody directed against Hif1*α*. Addition of a secondary antibody conjugated to HRP provides a sensitive colorimetric readout that is easily quantified by spectrophotometry. The HeLa-CoCl~2~ nuclear extracts provided with the commercial kit were used as a positive control of Hif1*α* transcriptional activity. Values are expressed as optical density (OD) at 450 nm with a reference wavelength of 655 nm.

Co-immunoprecipitation
----------------------

HepG2 cells were washed with ice-cold PBS and lysed in buffer containing 150 mℳ NaCl, 50 mℳ Tris--HCl, pH 7.4, 1% NP-40, 1 mℳ NaF, 1 mℳ Na~3~VO~4~, and EDTA-Free Halt Protease Inhibitor Cocktail (Thermo Scientific Pierce, Rockford, IL, USA) for 30 min on ice. Total cell lysates (1 mg of protein) were subjected to immunoprecipitation with 2 *μ*g of anti-phospho0STAT3 (Santa Cruz), anti-Hif1*α* (Abcam), and anti-Acetyl-CBP (Lys1535)/p300 (Lys1499) (Cell Signaling Technology, Danvers, MA, USA) for 1 h at 4 °C. Protein G Sepharose (GE Healthcare Bio-Sciences AB, Uppsala, Sweden) was added and incubation continued overnight at 4 °C. Precipitates were washed three times with ice-cold lysis buffer, resuspended in Laemmli buffer, and boiled for 10 min. Bound proteins were separated on an SDS--polyacrylamide gel and analysed by western blotting using the indicated antibodies.

ChIP assay
----------

Chromatin of cultured cells was fixed and immunoprecipitated according to [@bib5]. Cells were incubated with 100 *μ*ℳ CoCl~2~, 1 mℳ melatonin and both together for 24-h period. Then, cells were treated with 1% formaldehyde in PBS buffer by gentle agitation for 10 min at room temperature to crosslink proteins to DNA. Next, cells were washed, resuspended in lysis buffer and sonicated on ice for 8 × 15 s steps at a 20% output in a Branson Sonicator. Sonicated samples were centrifuged to clear supernatants. DNA content was quantified by picogreen (Life Technologies) and properly diluted to maintain an equivalent amount of DNA in all the samples (input DNA). For the immunoprecipitation of protein--DNA complexes, 4 *μ*g of specific antibody (anti-HIF1*α* NB100-134; NOVUS Biologicals, Littleton, CO, USA) and rabbit pre-immune IgG (sc-2027, Santa Cruz Biotechnology, Santa Cruz, CA, USA) (background DNA fraction) were added. Samples were incubated overnight at 4 °C on a 360° rotator (antibody-bound DNA fraction). Immunocomplexes were affinity absorbed with 60 *μ*l of protein G agarose/Salmon Sperm DNA (Millipore, Billerica, MA, USA) (pre-washed with lysis buffer for 1 h at 4 °C by gentle rotation), and collected by centrifugation (1000 r.p.m., 1 min). The antibody-bound and background DNA fractions were washed as described in [@bib5]. Crosslinks were reversed by adding 100 *μ*l of 10% Chelex (Bio-Rad Laboratories) and boiling for 10 min. The Chelex/protein G bead suspensions were incubated with proteinase K (20 mg ml^−1^) for 30 min at 55 °C while shaking, followed by another 10 min boiling. Suspensions were centrifuged and supernatants were collected. The eluates were used directly (input 1/5) as a template for Q-PCR with a LightCycler 480 instrument. Amplification was real-time monitored, stopped in the exponential phase of amplification and analysed by agarose gel electrophoresis. Amplifications of the VEGF gene sequences among the pull of DNA were performed with specific primers flanking from −1041 to −750 region, forward 5′-CAGGAACAAGGGCCTCTGTCT-3′, reverse 5′-TGTCCCTCTGACAATGTGCCATC-3′. The PCR conditions for the VEGF promoter region were 1 min at 94 °C, 1 min at 60 °C, 1 min at 72 °C. The amplification of the VEGF promoter region was analysed after 35 cycles.

Immunofluorescence analysis
---------------------------

To study the localisation of Hif1*α*, staining of Hif1*α* was performed on HepG2 cells. Cells were grown on coverslips for 24 h. Thereafter, cells were treated with melatonin as indicated. Cells were washed with PBS and fixed with 4% paraformaldehyde, permeabilised with 0.5% Triton X-100 in PBS, and pre-treated with blocking solution. After fixation and after blocking the non-specific binding, the coverslips were incubated with rabbit anti Hif1*α* (HIF1*α* NB100-134, NOVUS Biologicals) antibodies at 4 °C overnight. Thereafter, the secondary antibodies donkey anti-rabbit conjugated with FITC (Jackson Immuno Research, Baltimore, PA, USA). After washing, the coverslips were mounted on DakoCytomation Fluorescent Mounting Medium (DAKO). The preparations were analysed with an inverted fluorescence microscope (Nikon Eclipse Ti, Melville, NY, USA). Image analysis was performed using the ImageJ software v3.91 (<http://rsb.info.nih.gov/ij>). To quantify Hif1*α* nuclear translocation, results from fluorescence colocalisation studies were represented graphically in scatterplots where the intensity of one colour was plotted against the intensity of the second colour for each pixel. Nuclear regions were defined as 'region of interest\' (ROI) to determine Hif1*α* nuclear translocation, and the Pearson\'s correlation coefficient (PCC) was used as a statistic for quantifying colocalisation.

Statistical analysis
--------------------

Results are expressed as mean values±s.e.m. of the indicated number of experiments. A *t*-test was used to determinate differences between pairs of treatments, as indicate in results. One-way ANOVA followed by Student--Newmann--Keuls *post hoc* test was used to determine differences between the mean values of the different treated groups. *P*\<0.05 was considered as significant. Values were analysed using the statistical package Statistica 10.0 (Statsoft Inc, Tulsa OK, USA).

Results
=======

Effect of melatonin on VEGF levels and hypoxia-induced angiogenesis
-------------------------------------------------------------------

Oxygen deficiency is a hallmark of solid tumours that drives VEGF production and angiogenesis. To determine the effect of oxygen levels on angiogenesis-related factors in our *in vitro* model of HCC, HepG2 cells were incubated in normoxia or exposed to CoCl~2~ (100 *μ*ℳ) as a hypoxia mimetic in a kinetic experiment from 2 to 24 h.

As shown in [Figure 1A](#fig1){ref-type="fig"}, there was a hypoxia-dependent VEGF induction from the first 2 h of treatment, and an increase in the protein levels of Hif1*α* and phospho-STAT3 which reached a maximum at 24 h, time at which the inhibitory effect of the pharmacological melatonin concentration (1 mℳ) resulted more effective. Once our experimental conditions were set up and the use of CoCl~2~ as an effective hypoxia inductor confirmed, the 24-h time point was chosen for further experiments.

Beside growth factors and interleukins, hypoxia is the major VEGF inductor, which stimulates new capillary vessels formation to counteract low oxygen tension. Thus, in our experiments, 24 h of 100 *μ*ℳ CoCl~2~ treatment effectively enhanced VEGF mRNA levels ([Figure 1B](#fig1){ref-type="fig"}). Significant increases in VEGF protein expression and in the amount of VEGF released into the culture medium were also observed ([Figures 1C and D](#fig1){ref-type="fig"}). Moreover, as shown in [Figure 1](#fig1){ref-type="fig"}, melatonin did not exert a significant effect on protein levels in normoxia, only affecting the amount of secreted VEGF under these conditions. By contrast, melatonin treatment did clearly reduce hypoxia-induced VEGF expression and release to the medium.

To further confirm melatonin anti-angiogenic activity suggested by the induced decrease of VEGF levels under hypoxia, HUVECs tube formation assay was performed. HepG2 cells were cultured under conditions of CoCl~2~-induced hypoxia with or without the pharmacological concentration of melatonin (1 mℳ) for 24 h, and CM were applied to HUVECs in a series of angiogenic assays. As show in [Figure 1E](#fig1){ref-type="fig"}, hypoxia induced HUVECs to display their typical morphology and phenotype of endothelial cells, whereas this effect was prevented by melatonin treatment.

Melatonin inhibits hypoxia-induced Hif1*α* activation
-----------------------------------------------------

Once shown that melatonin anti-angiogenic activity is related with its ability to modulate VEGF levels, we next focused on elucidating the molecular mechanisms involved. Assuming that Hif1*α* is the major regulator of this endothelial growth factor, Hif1*α* mRNA levels and protein expression were measured in HepG2 cells exposed to normoxia or hypoxia and melatonin treatment. As expected, Hif1*α* transcription was induced by CoCl~2~ treatment, as shown by the increases in both mRNA and protein level. Similarly to the effects found on VEGF, only the 1 mM melatonin dose exerted an inhibitory effect on Hif1*α*-induced expression. However, while Hif1*α* protein expression was inhibited ([Figure 2A](#fig2){ref-type="fig"}), Hif1*α* mRNA levels did not decrease significantly after melatonin treatment ([Figure 2B](#fig2){ref-type="fig"}), even under hypoxia, suggesting that melatonin effects takes place at a post-transcriptional level.

It is widely accepted that to transcriptionally activate its target genes, Hif1*α* needs to translocate into the nucleus. Thus, we visualised its dynamic translocation by using fluorescence microscopy of HepG2 untreated or treated cells under normoxia or induced hypoxia. As show in [Figure 2C](#fig2){ref-type="fig"}, under normoxia, Hif1*α* was always located in the cytosol, and melatonin treatment did not affect its location. However, CoCl~2~ treatment induced Hif1*α* nuclear translocation, an effect that was prevented by melatonin 1 mM. Furthermore, results were consistent with those observed when measuring Hif1*α* ability to specifically bind the HRE. As shown in [figure 2D](#fig2){ref-type="fig"}, hypoxia significantly enhanced Hif1*α* transcription, while melatonin inhibited its activation in a dose-dependent manner.

Melatonin prevents hypoxia recruited STAT3/Hif1α/CBP/p300 within VEGF promoter
------------------------------------------------------------------------------

STAT3 is an essential mediator of VEGF transcription by direct binding to its promoter ([@bib46]). Furthermore, it induces Hif1*α* stability and enhances its transcriptional activity, behaving as a co-activator and conforming a transcriptional complex together with CBP/p300 ([@bib26]). Considering the close relationship between Hif1*α* and STAT3, we decided to analyse whether effects on Hif1*α* and VEGF expression could be mediated via STAT3 inhibition. As shown in [Figure 2A](#fig2){ref-type="fig"}, CoCl~2~ treatment resulted in STAT3 activation by phosphorylation at Tyr 705 residue, without affecting total STAT3 levels. However, this effect was prevented by incubation with melatonin 1 mM. Furthermore, melatonin effects under hypoxia were similar to those observed when HepG2 cells were exposed to the selective STAT3 inhibitor, Stattic ([Figures 3A and B](#fig3){ref-type="fig"}), and combined treatment with both melatonin and Stattic resulted in a synergic inhibitory effect on Hif1*α* and phospho-STAT3 activation and VEGF expression.

Since both functional Hif1*α* and phospho-STAT3 are known to be required for high VEGF activity ([@bib34]), and owing to the proximity of their binding sites within VEGF promoter, they are assumed to share a transcriptional complex together with CBP/p300. To analyse melatonin ability to disrupt the stability of this complex, we performed co-immunoprecipitation assay. As shown in [Figure 3C](#fig3){ref-type="fig"} CoCl~2~ treatment resulted in increased association between Hif1*α*, phospho-STAT3, and CBP/p300, confirming that they are likely linked. Furthermore, our results suggest that melatonin treatment inhibited this association and thus, VEGF transcriptional activation.

Although our data support the idea that melatonin prevents VEGF synthesis by blocking its transcription in HepG2 cells, a chromatin immunoprecipitation (ChIP) assay was performed under normoxia and hypoxia to investigate whether Hif1*α* occupancy of the VEGF promoter was affected by melatonin. As shown in [Figure 3D](#fig3){ref-type="fig"}. CoCl~2~-induced hypoxia resulted in enhanced promoter binding activity *vs* normoxia, and this effect was suppressed by 1 mM melatonin treatment.

Discussion
==========

HCC is the most common liver cancer, and even been the third-leading cause of cancer-related deaths worldwide, effective therapy is currently lacking ([@bib45]). This type of cancer is considered as a hypervascular tumour, and angiogenesis has a critical role in HCC growth and progression ([@bib61]). The high proliferation rate of tumour cells enhances local hypoxia within the HCC microenvironment; increasing new vessels formation for tumour oxygen and nutrients supply ([@bib38]), and allowing metastatic spreading by connection to the pre-existing vessels ([@bib11]). Although melatonin\'s ability to suppress angiogenesis mainly through VEGF downregulation has been shown in other tumour types ([@bib39]; [@bib36]), there are no reports about its anti-angiogenic activity in liver cancer. In the present study, we used the human liver cancer cell line HepG2 and HUVEC to analyse the potential anti-angiogenic activity of melatonin in HCC.

As indicated above, VEGF is an important growth factor implicated in cancer angiogenesis and can also be used as a tumour marker ([@bib35]; [@bib42]). Different studies have suggested that targeting the VEGF pathway could be even more effective strategy that targeting the tumour itself, based on the fact that angiogenesis and hypervascularisation is a common denominator of solid tumours, regardless their etiological origin ([@bib56]). In HCC, increased VEGF expression has been reported to correlate with tumour progression, microvessel invasion and metastasis of HCC ([@bib54]), and VEGF serum measurement are accepted to indirectly estimate tissue values, providing useful prognostic information for HCC management ([@bib48]). Although VEGF expression is driven by many factors, hypoxia seems to be the main regulator of its production ([@bib20]). Results from the present study verified that incubation of cells with CoCl~2~ mimics the hypoxia situation, as confirmed by the observed increase of VEGF protein expression and secretion *vs* normoxia. Moreover, VEGF levels were effectively reduced by melatonin treatment, mainly at the tested pharmacological dose. Thus, and since microvessels density reflects tumour angiogenicity, and is considered vital for tumour prognostic ([@bib37]; [@bib55]), we performed *in vitro* tube formation assay, as a widely accepted approach to measure the reorganisation stage of angiogenesis, under our experimental conditions. Results showed that melatonin treatment decreased VEGF secretion by HepG2 cells; therefore, HUVECs cultured with CM from the melatonin treated group were unable to display its endothelial features. Similarly to our findings, melatonin has been previously shown to inhibit human pancreatic carcinoma cell PANC-1-induced HUVECs proliferation and migration by inhibiting VEGF expression ([@bib17]).

Once confirmed the anti-angiogenic properties of melatonin, we focused on elucidating the responsible molecular mechanism. Results showed a hypoxia-dependent activation of VEGF transcriptional regulators, Hif1*α* and phospho-STAT3, which were also inhibited by melatonin at the pharmacologic concentration, 1 mℳ. The present data suggest that melatonin anti-angiogenic activity in liver cancer cells may be mediated, at least in part, by inhibition of Hif1*α* nuclear translocation, required for its transcriptional activation and subsequent VEGF expression. Moreover, results reported in other tumour types also point to melatonin ability to modulate Hif1*α* activity ([@bib18]; [@bib47]; [@bib13]; [@bib2], [@bib3]).

STAT3 has been shown to be a potential modulator of Hif1*α*-mediated VEGF expression, and the development of STAT3 inhibitors may be of interest for clinical treatment, especially of solid tumours ([@bib33]). In this regard, molecules like betulinic acid, with anti-cancer and anti-inflammatory properties similar to melatonin, have been reported to suppress angiogenesis via STAT3 and Hif1*α* inhibition in PC-3 prostata cancer cells ([@bib53]). Micro RNAs like miR-20b, which are known to regulate cellular processes such as proliferation and angiogenesis, have been documented to modulate VEGF expression by targeting HIF-1*α* and STAT3 in MCF-7 breast cancer cells ([@bib10]). Consistently, in the present study we observed a decrease of STAT3 activation after melatonin treatment. Combined treatment with the STAT3 inhibitor Stattic, known to prevent STAT3 activation, dimerisation and nuclear translocation ([@bib51]); resulted in a synergic effect, with a decrease in VEGF production, via inhibition of the activation of Hif1*α* and STAT3 required for optimal VEGF synthesis. This suggests that melatonin anti-angiogenic effects may due to its ability to prevent STAT3 activation, which normally increases Hif1*α* stability and enhances its transcriptional activity.

Although previous studies reported that either Hif1*α* or STAT3 alone transcriptionally activate VEGF expression ([@bib43]; [@bib50]), some evidence suggest that a maximal induction is reached when both transcription factors bind to the VEGF promoter, where they are presumably linked within the same transcriptional complex together with CBP/p300 co-activator ([@bib26]; [@bib49]). Considering the importance of this active complex for an efficient VEGF production, we hypothesised that melatonin effects could be related with its capacity to interrupt this transcriptional complex stability. Thus, while hypoxia induced by CoCl~2~ treatment resulted in increased association between Hif1*α*, phospho-STAT3, and CBP/p300, melatonin was able to prevent the physical interaction between these proteins, as confirmed by the immunoprecipitation assays. Moreover, our ChIP experiments revealed that Hif1*α* occupancy of the VEGF promoter was affected by melatonin treatment, providing final evidence to support a hypothetic model of melatonin inhibition of hypoxia-induced angiogenesis in HCC, which is depicted in [Figure 4](#fig4){ref-type="fig"}. Results observed at the higher melatonin dose may be, in some aspect, related with the exceptionally high physiological concentrations of melatonin in the bile of mammals ([@bib57]), suggesting that hepatocytes may have a particular ability to concentrate melatonin, and so pharmacologic doses may be especially effective in inhibiting liver cancer.

Summarising, this is the first report showing that Hif1*α* and STAT3 transcription factors promote VEGF production in hypoxia-related angiogenesis in HCC. Considering the results from the current study and previous research data ([@bib8], [@bib9]), as well as the lack of toxicity of melatonin even at high doses, it seems reasonable to recommend further research to test the usefulness of the indole for the prevention and treatment of liver cancer in patients.
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![**Effect of melatonin on VEGF levels and hypoxia-induced angiogenesis.** HepG2 cells were incubated in normoxia or exposed to CoCl~2~ (100 *μ*ℳ) as a hypoxia mimetic in a kinetic experiment from 2 to 24 h, and VEGF, Hif1*α* phospho-STAT3, and STAT3 protein expression was analysed by western blot (**A**). Effect of normoxia/hypoxia and melatonin treatments on VEGF mRNA levels (**B**), VEGF cell protein levels (**C**) and VEGF secreted to the culture media (**D**). HUVECs tube formation assay (**E**). Tube formation index (S.CORE) (**F**). Data are expressed as a percentage of mean values±s.e.m. of four experiments performed in triplicate. \**p*\<0.05 significant differences *vs* control. ^\#^*P*\<0.05 significant differences between CoCl~2~ and melatonin+CoCl~2~-treated cells.](bjc2013285f1){#fig1}

![**Melatonin inhibits hypoxia-induced Hif1*α* activation.** Effect of normoxia/hypoxia and melatonin treatments on protein levels (**A**), Hif1*α* mRNA levels (**B**), and Hif1*α* nuclear translocation (**C**). Scatterplots of green and blue green pixel intensities and Pearsońs correlation coefficient (PCC) (**D**). Effect of melatonin treatment on Hif1*α* transcriptional activity. HeLa cell nuclear extracts treated with CoCl~2~ provided with the kit were used as a positive control for Hif1*α* activation (**E**). Data are expressed as a percentage of mean values±s.e.m. of four experiments performed in triplicate. \**p*\<0.05 significant differences *vs* control. ^\#^*P*\<0.05 significant differences between CoCl~2~ and melatonin+CoCl~2~-treated cells.](bjc2013285f2){#fig2}

![**Melatonin prevents hypoxia recruited STAT3/Hif1α/CBP/p300 within VEGF promoter.** VEGF secreted protein from HepG2 cells under normoxia/hypoxia, with or without melatonin treatment and exposed to the selective STAT3 inhibitor, Stattic (**A**). Hif1*α*, phospho-STAT3, STAT3, and VEGF protein expression in HepG2 cells under normoxia/hypoxia, with or without melatonin treatment and exposed to the selective STAT3 inhibitor, Stattic (**B**). Effect of hypoxia and/or melatonin treatment on Hif1*α*, phospho-STAT3, and CBP/p300 association measured by co-immunoprecipitation (**C**). Effect of melatonin on Hif1*α* binding to VEGF promoter region analysed by ChIP. M: marker; IgG: Rabbit control IgG (**D**). Data are expressed as a percentage of mean values±s.e.m. of four experiments performed in triplicate. \**p*\<0.05 significant differences *vs* control. ^\#^*P*\<0.05 significant differences between CoCl~2~ and melatonin+CoCl~2~-treated cells.](bjc2013285f3){#fig3}

![**Model of melatonin inhibition of hypoxia-induced angiogenesis in HCC.** Hif1 is the major regulator of oxygen homeostasis. Whereas normoxia induces Hif1*α* proteosomal degradation, under hypoxia is stabilised and translocates to the nucleus where it forms a complex with phospho-STAT3 and CBP/p300 to upregulate VEGF expression, and thus hypoxia-induced angiogenesis. Melatonin pharmacological doses exert anti-angiogenic effects through inhibition of the previously described molecular mechanism.](bjc2013285f4){#fig4}
